Intel stock spikes after report of possible US government stake
Doximity , Inc. (NYSE:DOCS) Chief Executive Officer Jeffrey Tangney recently sold shares worth approximately $75.7 million, according to a recent SEC filing. The transactions involved the sale of Class A Common Stock over February 11 and 12, with prices ranging from $74.86 to $78.86 per share. The stock has shown remarkable momentum, delivering a 159% return over the past year and currently trades at $76.94. According to InvestingPro analysis, the company appears overvalued at current levels.
On February 11, Tangney executed several sales, including 159,108 shares at a weighted-average price of $75.83, 19,226 shares at $76.21, and 10,760 shares at $75.75. Additional transactions included 18,158 shares sold at $76.90 and 20,482 shares at $78.05. A smaller transaction of 600 shares was completed at $78.86.
The following day, February 12, saw further sales, including 260,624 shares at $74.86, 27,433 shares at $75.33, and 474,448 shares at $75.33. Another 13,052 shares were sold at $75.83.
These transactions reflect Tangney’s continued involvement in managing his holdings in Doximity, a leading digital platform for medical professionals.
In other recent news, Doximity has been making headlines with significant developments. The company’s third-quarter results showcased robust growth and profitability, exceeding expectations with a growth rate surpassing 25% and an EBITDA margin above 60%. Notably, the company’s fiscal third-quarter 2025 revenue reached $168 million, a 25% year-over-year increase, surpassing both the Street’s and the company’s own guidance. This strong financial performance has led to various analyst upgrades and price target revisions. Jefferies raised the price target for Doximity to $88, maintaining a Buy rating. Mizuho (NYSE:MFG) Securities also increased its price target to $65, while Piper Sandler upgraded the company’s shares from Neutral to Overweight, raising the price target to $78. KeyBanc Capital Markets reiterated an Overweight rating with a $65.00 price target, and Needham increased its price target to $82, maintaining a Buy rating. These recent developments underscore Doximity’s continued growth trajectory and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.